
Orla DTx
Our mission is to become one of the leading digital therapeutics developers.
Partner with us
We develop Digital Therapeutics solutions to treat serious disease together with our partners in Pharma, Diagnostics and MedTech.
The company
Orla DTx is a Finnish Digital Therapeutics company based in Helsinki.
The company was founded 2020.
The company
Orla’s experienced core team has a 360o understanding of DTx research, development and commercialization.
Our experience in technology, healthcare, market access, regulatory, commercialization and especially our understanding of pharma enable us to provide our customers with a clear view of the best DTx opportunities.
Our track record of building and commercializing DTxs, our network of development partners and exceptional access to data in our home market help us to develop DTxs in an agile and effective way.
Our Experts
Latest news
5.9.2023
Updates made to the Remote Monitoring (Etämittaus) mobile application
5.6.2023 The servers of Orla Etämittaus will be updated on Monday June 19th between 17:00 and 22:00. Patients can use ...
8.6.2021
Don’t buy a pig in a poke: what should be required of a digital health care solution?
All kinds of stories concerning healthcare digitalization have been flooding from every outlet for most of the past decade. No ...
25.5.2021
What kind of digital solution can improve the diagnosis or treatment of asthma?
Inaccurate and forgotten PEF measurement results eventually accelerated the development of digital asthma treatment solutions. Now, thousands of measurement results ...
11.5.2021
In February, Kymsote began a trial period of the digital treatment pathway for asthma patients
The pilot of the digitalized treatment pathway in Kymsote (wellbeing services county of Kymenlaakso) was successfully launched at the Karhula ...
1.3.2021
The healthcare remote monitoring business of Elisa Oyj has been acquired by Orla DTx Oy
Orla DTx Oy focuses on enhancing treatment pathway effectiveness through digitalization, Elisa Oyj will continue as one of the shareholders ...